


## PHARMACEUTICAL 2022



## Aptevo Therapeutics Inc. Rank 309 of 475





## PHARMACEUTICAL 2022

## Aptevo Therapeutics Inc. Rank 309 of 475



The relative strengths and weaknesses of Aptevo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aptevo Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 45% points. The greatest weakness of Aptevo Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is -204%, being 72% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	52,570
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	34,757
Liabilities, Non-Current	1,341
Other Assets	1,652
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	19,287
Other Net Income	-7,057
Property and Equipment	2,379
Research and Development	18,994
Revenues	12,292
Selling, General and Administrative Expense	14,698

Output Variable	Value in 1000 USD
Assets	56,601
Liabilities	55,385
Expenses	33,692
Stockholders Equity	1,216
Net Income	-28,457
Comprehensive Net Income	-28,457
Economic Capital Ratio	-204%